First-dose anaphylaxis to infliximab: a case of mammalian meat allergy

Chitnavis, Maithili V.; Stein, Daniel J.; Commins, Scott P.; Schuyler, Alex; Behm, Brian W.

doi:10.1016/j.jaip.2017.04.044

Cited by 28 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with mammalian meat allergy and chemotherapy‐refractory metastatic malignancy, the EGFR inhibitor panitumumab, a human antibody, has been reported as an alternate therapeutic agent . Similar acute immunological responses have been observed in patients with mammalian meat allergy exposed to infliximab and snake antivenom in isolated case reports . Notably, all these cases of acute reactions to α ‐gal have occurred when the culprit allergen has been introduced intravenously.…”

Section: Immediate Anaphylaxis: Cetuximabmentioning

confidence: 69%

See 1 more Smart Citation

Mammalian meat allergy

Wong

Sebaratnam

2018

Int J Dermatology

View full text Add to dashboard Cite

Mammalian meat allergy is an allergic reaction mediated by IgE antibodies directed against the mammalian oligosaccharide epitope galactose-α-1,3-galactose. Clinically, it is characterized by a range of symptoms including urticaria, angioedema, gastroenteritis, and anaphylaxis hours following ingestion of red meat. It is an emergent allergy in tick endemic areas across the world. As a recently described disease with a cutaneous presentation, dermatologists should be familiar with this entity and recognize it as a differential diagnosis for urticarial and anaphylaxis reactions.

show abstract

Section: Immediate Anaphylaxis: Cetuximabmentioning

confidence: 69%

“…22 Similar acute immunological responses have been observed in patients with mammalian meat allergy exposed to infliximab and snake antivenom in isolated case reports. 23,24 Notably, all these cases of acute reactions to a-gal have occurred when the culprit allergen has been introduced intravenously.…”

Section: Immediate Anaphylaxis: Cetuximabmentioning

confidence: 99%

Mammalian meat allergy

Wong

Sebaratnam

2018

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…While biologic agents have revolutionized the therapies for chronic inflammatory, neoplastic, and autoinflammatory disease, like other pharmaceutical agents, they can cause anaphylactic reactions. Anaphylaxis has been reported with various BAs, including rituximab, infliximab, and tocilizumab in pediatric rheumatic diseases [17][18][19][20][21]. Anaphylactic reactions to BAs can occur on the first dose or after multiple exposures [22].…”

Section: Discussionmentioning

confidence: 99%

Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey

et al. 2020

View full text Add to dashboard Cite

Objectives: Juvenile idiopathic arthritis is the most common rheumatic disease in childhood. Biologic agents have changed the course of juvenile idiopathic arthritis. However, there are concerns regarding the occurrence of serious adverse events in patients receiving biologic agents. The aim of this study was to evaluate adverse events in children with juvenile idiopathic arthritis receiving biologic agents. Material and methods: This retrospective study includes juvenile idiopathic arthritis patients receiving biologic agents. Demographic features and adverse events during biologic agents were collected from medical files. Adverse events that either resulted in death, were life-threatening, required inpatient hospitalization, or resulted in persistent or significant disability/incapacity were considered as serious adverse events. Results: In total, 162 juvenile idiopathic arthritis patients (55.6% female) receiving biologic agents were enrolled: 101 (62.3%) patients treated with etanercept, 27 (16.7) with tocilizumab, 14 (8.6%) with adalimumab, 15 (9.2%) with anti-interleukin 1 agents (13 canakinumab, 2 anakinra), and 5 (3.1%) with infliximab. 75.9% of the patients received concomitantly disease-modifying anti-rheumatic drugs, and 20.4% received disease-modifying anti-rheumatic drugs plus corticosteroid. The mean age at initiation of the biologic agent was 10.5 ±4.3 years. The mean age at the study enrolment was 12.1 ±4.5 years. The mean follow-up duration was 19.7 ±2.1 months. The most frequent adverse event was upper respiratory tract infections (54.3%) followed by urinary tract infections (21%). Anaphylaxis occurred in 3 patients (1.9%): 2 with tocilizumab and one with infliximab. Macrophage activation syndrome occurred in 1 patient (0.6%) receiving tocilizumab. Lung tuberculosis developed in 2 patients (1.2%) receiving canakinumab. The frequency of serious adverse events in total was 6.7%. Conclusions: While the most frequent adverse events during biologic agents was upper respiratory tract infections, the frequency of serious adverse events was 6.7%; therefore, juvenile idiopathic arthritis patients receiving biologic agents should be carefully evaluated for these adverse events in clinical practice.

show abstract

“…The risk of an anaphylactic reaction to those antibodies and to antibodies carrying the α-Gal epitope on the Fc part of the antibody was estimated to be very low. However, a recent case reported an anaphylactic reaction to infliximab, a monoclonal antibody carrying an α-Gal epitope on the Fc part and produced in SP2/0 cells [ 48 ].…”

Section: α-Gal Is Present In Many Non-food Sourcesmentioning

confidence: 99%

Role and Mechanism of Galactose-Alpha-1,3-Galactose in the Elicitation of Delayed Anaphylactic Reactions to Red Meat

Hilger

Fischer

Wölbing

et al. 2019

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of ReviewThe alpha-Gal (α-Gal) syndrome is characterized by the presence of IgE antibodies directed at the carbohydrate galactose-alpha-1,3-galactose (α-Gal). In this article, we review the presence of α-Gal in food and non-food sources; we discuss the evolutionary context of the antibody response to α-Gal and highlight immune responses to α-Gal and other carbohydrates.Recent findingsIgE antibodies have been associated with delayed allergy to red meat. In addition to food, drugs, and other products of animal origin are increasingly perceived as a risk for patients sensitized to α-Gal. The link between tick bites and anti-α-Gal IgE-antibody production that has been established first by epidemiological studies has now been confirmed in mouse models.SummaryThe anti-α-Gal immune response is complex and characterized by a unique feature. IgM and IgG antibodies have been found to confer protection against pathogens whereas the IgE-response to α-Gal is detrimental and causes severe reactions upon exposure to mammalian meat and other products.

show abstract

First-dose anaphylaxis to infliximab: a case of mammalian meat allergy

Cited by 28 publications

References 9 publications

Mammalian meat allergy

Mammalian meat allergy

Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey

Role and Mechanism of Galactose-Alpha-1,3-Galactose in the Elicitation of Delayed Anaphylactic Reactions to Red Meat

Contact Info

Product

Resources

About